PD-L1 Expression in Kidney Cancer
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in kidney cancer and developing biomarkers for anti-PD-L1 agents.
David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses PD-L1 expression in kidney cancer and developing biomarkers for anti-PD-L1 agents.
Clinical Pearls:
- A tumor that uses PD-L1 as a defense might be more likely to respond to an agent that targets the interaction between the T cell and the tumor
- In kidney cancers, there are patients that do not express PD-L1 but are responding to anti-PD-L1 agents
- Tumors in kidney cancers are heterogeneous and different aspects of the tumor will express PD-L1 while other places in the tumor will not
- Researchers are looking at the difference between the primary tumors and their metastases in terms of PD-L1 expression to try to determine which patients will benefit the most from treatment
<<<
Isatuximab Plus VRd Enhances MRD Negativity and Responses in Transplant-Ineligible NDMM
December 10th 2024The phase 3 IMROZ trial showed isatuximab plus VRd and Rd maintenance improved MRD negativity and responses versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
